UK unveils “real difference” bioscience industry strategy
This article was originally published in Clinica
Executive Summary
A £180m ($281m) Biomedical Catalyst Fund is one of the headline initiatives of a new UK bioscience industry strategy. This and a raft of other groundbreaking, practical initiatives presented at the highest levels of industry and government promise to breathe new life into UK healthcare products manufacturing.